Table 2.
Clinical and immunological profile of study participants.
| Parameters | Sub-types | All patients (%) | Active on 1st Line ART | Failed 1st Line ART | P |
|---|---|---|---|---|---|
|
| |||||
| 263 (76.23) | 82 (23.77) | - | |||
|
| |||||
| Baseline WHO clinical stage | I | 201 (58.26) | 153 (76.0) | 48 (24) | .985 |
| II | 66 (19.13) | 51 (77.27) | 15 (22.73) | ||
| III | 70 (20.29) | 53 (75.71) | 17 (24.29) | ||
| IV | 8 (2.32) | 7 (75.00 | 2 (25) | ||
|
| |||||
| First line ART regimen | ZDV/3TC/NVP or EFV | 251 (72.75) | 214 (85.26) | 37(14.74) | .001 |
| D4T/3TC/NVP or EFV | 22 (6.38) | 19 (86.36 ) | 3 (13.64) | ||
| TDF/3TC/NVP or EFV | 68 (19.71) | 29 ( 42.65) | 39 ( 57.35) | ||
| ABC/3TC/NVP or EFV | 4 (1.16) | 1 ( 25.00) | 3 (75.00) | ||
|
| |||||
| ART duration | <12 months | 11 (3.19) | 11 (100) | 0 (0) | .022 |
| −59 months | 19 (5.51) | 18 (94.74) | 1 (5.26) | ||
| >60 months | 315 (91.30) | 234 ( 74.29) | 81 (25.71) | ||
|
| |||||
| CD4 count at enrolment | <200 | 106 (30.72) | 70 (66.04) | 36 (33.96) | .001 |
| 200–349 | 101 (29.28) | 73 (72.28) | 28 ( 27.72) | ||
| ≥350 | 138 (40.00) | 120 (86.96) | 18 (13.04) | ||
|
| |||||
| Baseline BMI | <25 | 218 (63.19) | 85 (68.00) | 40 (32.00) | .025 |
| 25–29.9 | 85 (24.64) | 87 (80.56) | 21 (19.44) | ||
| ≥30 | 42 (12.17) | 91 (81.25) | 21 (18.75) | ||
|
| |||||
| Adherence level | <95 | 232 (67.25) | 97(85.84) | 16 (14.16) | .003 |
| >95 | 113 (32.75) | 166 (71.55) | 66 (28.45) | ||
|
| |||||
| Change in 1st line ART regimen | No change ART regimen change |
236 (80.55) 57 (19.45) |
166 (70.34) 48 (84.21) |
70 (29.66) 9 (15.79) |
.034 |